Does post-operative radiochemotherapy improve survival in high-grade endometrial cancer patients? Results of a population-based cohort analysis of a cancer registry
Adjuvant treatment of high-grade endometrial cancer varies greatly due to the lack of definitive results from controlled randomized trials on the subject. In a retrospective study, we sought to investigate the influence of post-operative radio-, chemo, and radiochemotherapy on survival time and recurrence rates among high-grade endometrial cancer patients.
284 high-grade endometrial cancer patients (FIGOI–III, or unknown classification) diagnosed between 1998 and 2015 were retrospectively analyzed. All patients underwent surgery. Overall survival (OS), recurrence-free survival (RFS), and recurrence rates were compared for post-operative treatment modalities of radiotherapy alone (RT), chemotherapy alone (CTX), radiochemotherapy (RCT), and observation (OBS).
Post-operative RCT and RT resulted in a significantly improved 5-year OS of 94.1% (HR 0.104, CI 0.013–0.809) and 62.1% (HR 0.615, CI 0.390–0.969), respectively, compared to 43.6% for OBS. CTX did not significantly improve OS leading to a 5-year OS of 56.5% (HR 0.783, CI 0.224–2.740). 5-year recurrence rate was lowest for patients treated with RCT (5.3%). 5-year RFS was 94.1% for the RCT group and proved to be significantly superior to 58.8% for RT (HR 9.034, CI 1.184–68.948), 56% for CTX (HR 12.738, CI 1.337–121.346), and 37.4% for OBS (HR 16.407, CI 2.127–126.575), respectively. In comparison with OBS, RT alone resulted in a significant improvement in RFS (HR 0.551, CI 0.354–0.856).
Our retrospective population-based study indicates a survival benefit from treating high-grade endometrial cancer with post-operative RCT. Randomized controlled trials are needed to minimize potential confounding parameters and further clarify the subject.
KeywordsEndometrial cancer Radiotherapy Chemotherapy Adjuvant treatment
Protocol/project development: Scharl S, Papathemelis T, Scharl A, Kölbl O, and Klinkhammer-Schalke M. Data collection or management: Kronberger K and Gerken M. Data analysis: Kronberger K, Gerken M, and Scharl S. Manuscript draft: Scharl S. Manuscript revision: Papathemelis T, Scharl A, Kölbl O, and Klinkhammer-Schalke M
No funding was obtained
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics approval and consent to participate: due to the analysis of data from a clinical cancer registry, no ethics approval was necessary. This was confirmed by the Ethics Committee at the Regensburg University, Regensburg, Germany.
- 1.A phase III trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate- or high-risk endometrial cancer. ENGOT-EN2-DGCG/EORTC 55102. http://meetinglibrary.asco.org/record/98495/abstract. Zugriff am 4.6.2017
- 12.Koh W-J, Greer B, Abu-Rustum N, Campos SM. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) Uterine Neoplasms. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Zugriff am 14.5.2017
- 16.Pelvic radiation therapy or vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk Stage I or Stage II endometrial cancer—full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00807768. Zugriff am 31.5.2017
- 18.Selective targeting of adjuvant therapy for endometrial cancer (STATEC)—full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02566811. Zugriff am 31.5.2017
- 19.Selective targeting of adjuvant therapy for endometrial cancer (STATEC)—tabular view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/record/NCT02566811. Zugriff am 23.1.2017